As of 30 Sep 2025, 27 institutional investors reported holding $603,281,000 in principal (par value) of IONIS PHARMACEUTICALS INC - NOTE 4/0.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | $603,281,000 | $742,167,044 | +$54,211,018 | 122.7% | 27 |
| 2025 Q2 | $549,711,910 | $555,202,909 | +$4,432,717 | 100.77% | 33 |
| 2025 Q1 | $546,181,909 | $539,251,665 | -$12,261,391 | 98.43% | 34 |
| 2024 Q4 | $561,167,910 | $543,386,109 | +$17,584,000 | 96.68% | 47 |
| 2024 Q3 | $542,279,000 | $542,910,983 | -$45,375,270 | 99.73% | 57 |
| 2024 Q2 | $589,177,000 | $608,248,104 | +$386,087 | 102.99% | 56 |
| 2024 Q1 | $590,897,000 | $584,045,653 | +$7,085,229 | 98.69% | 58 |
| 2023 Q4 | $585,686,397 | $624,942,733 | -$1,937,571 | 105.49% | 53 |
| 2023 Q3 | $582,815,846 | $1,198,389,919 | +$596,945,679 | 97.92% | 54 |
| 2023 Q2 | $581,295,500 | $550,563,087 | +$49,660,064 | 94.7% | 50 |
| 2023 Q1 | $537,196,524 | $492,158,927 | -$3,635,393 | 91.18% | 43 |
| 2022 Q4 | $557,023,500 | $516,828,897 | -$3,314,203 | 92.79% | 42 |
| 2022 Q3 | $485,462,000 | $465,877,923 | -$14,577,248 | 99.26% | 39 |
| 2022 Q2 | $505,388,900 | $438,363,173 | +$438,355,273 | 91.0% | 33 |